

RESEARCH ARTICLE

Open Access

PIK3CA mutation impact on survival in breast cancer patients and in ER α , PR and ERBB2-based subgroups

Magdalena Cizkova^{1,2}, Aurélie Susini¹, Sophie Vacher¹, Géraldine Cizeron-Clairac¹, Catherine Andrieu¹, Keltouma Driouch¹, Emmanuelle Fourme³, Rosette Lidereau¹ and Ivan Bièche^{1*}

Abstract

Introduction: *PIK3CA* is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of *PIK3CA* mutation status is controversial.

Methods: We investigated the prognostic significance of *PIK3CA* mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years).

Results: *PIK3CA* mutations were identified in 151 tumors (33.4%). The frequency of *PIK3CA* mutations differed markedly according to hormone receptor (estrogen receptor alpha [ER α] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2-subgroup. *PIK3CA* mutation was associated with significantly longer metastasis-free survival in the overall population ($P = 0.0056$), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of *PIK3CA* mutation status persisted only in the ERBB2-positive subgroup.

Conclusions: This study confirms the high prevalence of *PIK3CA* mutations in breast cancer. *PIK3CA* mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of *PIK3CA* mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.

Introduction

Dysregulation of tyrosine kinase receptor (TKR)-phosphatidylinositol 3-kinase (PI3K) signaling pathways is frequent in human cancers. Among the most important molecular events downstream of TKR activation is PI3K activation, which catalyzes the phosphorylation of inositol lipids to phosphatidylinositol-3,4,5-trisphosphate. Phosphatidylinositol-3,4,5-trisphosphate activates the serine/threonine kinase AKT, which in turn regulates several signaling pathways controlling cell survival, apoptosis, proliferation, motility, and adhesion [1]. PI3K is a heterodimeric enzyme composed of a p110 α

catalytic subunit encoded by the *PIK3CA* gene and a p85 regulatory subunit encoded by the *PIK3R1* gene [2].

Recently, gain-of-function mutations in *PIK3CA* have been found in several cancers, including breast cancer [1,3,4]. *PIK3CA* is frequently mutated at 'hotspots' in exons 9 and 20, corresponding to the helical (E542K and E545K) and kinase (H1047R) domains, respectively. P110 α carrying a hotspot mutation shows oncogenic activity: it can transform primary fibroblasts in culture, induce anchorage-independent growth, and cause tumors in animals [5,6].

After the *TP53* suppressor gene, the *PIK3CA* oncogene is the most frequently mutated gene in human breast cancers; mutations are observed in 20% to 40% of cases [7,8]. Mutation is an early event in breast cancer and is more likely to play a role in tumor initiation than in invasive progression [9]. It is noteworthy that

* Correspondence: ivan.bieche@curie.net

¹Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France

Full list of author information is available at the end of the article

activating somatic mutations of other oncogenes (*EGFR*, *KRAS*, *HRAS*, *NRAF*, *BRAF*, *AKT1*, and so on) involved in molecular events downstream of TKR activation and frequently observed in other cancers are rare in breast cancer. Several studies of breast cancer suggest that *PIK3CA* mutations are more frequent in estrogen receptor-alpha-positive ($ER\alpha^+$) breast tumors (30% to 40%) than in receptor-alpha-negative ($ER\alpha^-$) breast tumors (10% to 20%) [3,7,10,11].

The prognostic value of *PIK3CA* mutation status in breast cancer is controversial. Li and colleagues [12] suggested that mutations in any part of the gene may be related to poor clinical outcome. On the contrary, Maruyama and colleagues [13], Pérez-Tenorio and colleagues [14], and Kalinsky and colleagues [11] suggested that *PIK3CA* mutations were significantly and independently associated with better recurrence-free survival. In particular, Kalinsky and colleagues [11] studied a series of 590 patients with breast cancer with a median follow-up of 12.8 years and found 32.5% of *PIK3CA* mutations. *PIK3CA*-mutated status was associated with markers of good prognosis and with significant improvement in overall ($P = 0.03$) and breast cancer-specific ($P = 0.004$) survival [11]. A study focused specifically on recurrent and metastatic breast cancer found a significant association of *PIK3CA* mutations and longer relapse-free survival [15]. Barbareschi and colleagues [16] reported that only *PIK3CA* exon 9 mutations were independently associated with early recurrence and death but that exon 20 mutations were associated with favorable outcome. Several teams have found no significant effect of *PIK3CA* mutations on patient outcome [7,8,17,18]. It is, however, noteworthy that Loi and colleagues [18] identified an expression signature derived from exon 20 *PIK3CA*-mutated tumors. This signature predicted better outcome in ER^+ breast cancer. In particular, the clinical consequences of *PIK3CA* mutations might vary according to the status of well-known molecular markers in breast cancer, namely *ER* α , progesterone receptor (*PR*), and *ERBB2*. Here, we examined the prognostic value of *PIK3CA* mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome, taking *ER* α , *PR*, and *ERBB2* status into account.

Materials and methods

Patients and samples

We analyzed samples of 452 primary unilateral invasive primary breast tumors excised from women at the Institut Curie/Hôpital René Huguenin (Saint-Cloud, France) from 1978 to 2008. All patients who entered our institution before 2007 were informed that their tumor samples might be used for scientific purposes and had the opportunity to decline. Since 2007, patients entering our

institution have given their approval also by signed informed consent. This study was approved by the local ethics committee (Breast Group of René Huguenin Hospital). The samples were examined histologically and were considered suitable for this study if the proportion of tumor cells exceeded 70% with sufficient cellularity as was proven by evaluation of tumor samples stained by hematoxylin and eosin. Immediately after surgery, the tumor samples were placed in liquid nitrogen until RNA extraction.

The patients (mean age of 61.6 years and range of 31 to 91) met the following criteria: primary unilateral non-metastatic breast carcinoma, with full clinical, histological and biological data; no radiotherapy or chemotherapy before surgery; and full follow-up at Institut Curie/Hôpital René Huguenin.

One hundred sixty patients (35.4%) had breast-conserving surgery plus locoregional radiotherapy, and 292 patients (64.6%) had modified radical mastectomy. Clinical examinations were performed every 3 or 6 months during the first 5 years, according to the prognostic risk of the patients, and then yearly. Mammograms were done annually. Three hundred sixty-six patients received adjuvant therapy, consisting of chemotherapy alone in 94 cases, hormone therapy alone in 177 cases, and both treatments in 95 cases. None of the $ERBB2^+$ patients was treated with anti-*ERBB2* therapy. The histological type and number of positive axillary nodes were established at the time of surgery. The malignancy of infiltrating carcinomas was scored with the Scarff-Bloom-Richardson histoprognostic system'.

ER and *PR* status was determined at the protein level by using biochemical methods (dextran-coated charcoal method or enzymatic immunoassay) until 1999 and later by using immunohistochemistry. Cutoff for *ER* and *PR* positivity was set at 15 fm/mg (dextran-coated charcoal or enzyme immunoassay) and at 10% immunostained cells (immunohistochemistry). A tumor was considered $ERBB2^+$ by immunohistochemistry if it scored 3 or more with uniform intense membrane staining of greater than 30% of invasive tumor cells. Tumors scoring 2 or more were considered to be equivocal for *ERBB2* protein expression and were tested by fluorescence *in situ* hybridization for *ERBB2* gene amplification. In all cases, the *ER* α , *PR*, and *ERBB2* status was confirmed by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) with cutoff levels based on previous studies comparing results of the mentioned methods [19-22]. On the basis of hormone receptor (HR) (*ER* α and *PR*) and *ERBB2* status, we subdivided the 452 patients into four subgroups: HR⁺ (ER^+ or PR^+ or both)/ $ERBB2^+$ ($n = 53$), HR⁺ (ER^+ or PR^+ or both)/ $ERBB2^-$ ($n = 287$), HR⁻ (ER^- and PR^-)/ $ERBB2^+$ ($n = 48$), and HR⁻ (ER^- and PR^-)/ $ERBB2^-$ ($n =$

64). Standard prognostic factors are reported in Table S1 of Additional file 1. The median follow-up was 10.0 years (range of 13 months to 28.9 years). One hundred seventy patients developed metastases.

RNA extraction

Total RNA was extracted from breast tumor samples by using the acid-phenol guanidium method. RNA quantity was assessed by using a NanoDrop Spectrophotometer ND-1000 with its corresponding software (Thermo Fisher Scientific Inc., Wilmington, DE, USA). RNA quality was determined by electrophoresis through agarose gel and staining with ethidium bromide. The 18S and 28S RNA bands were visualized under ultraviolet light. DNA contamination was quantified by using a couple of primers located in an intron of gene coding for albumin (ALB) (Gene ID: 213). Samples were further used only when the cycle threshold (Ct) obtained by using these ALB intron primers was greater than 40.

PIK3CA mutation screening

PIK3CA mutations were detected by screening cDNA fragments obtained by RT-PCR amplification of exons 9 and 20 and their flanking exons. Details of the primers and PCR conditions are available on request. The amplified products were sequenced with a BigDye Terminator kit on an ABI Prism 3130 automatic DNA sequencer (Applied Biosystems, Courtabœuf, France) with detection sensitivity of 5% mutated cells, and the sequences

were compared with the corresponding cDNA reference sequence (NM_006218). All of the detected PIK3CA mutations were confirmed in the second independent run of sample testing.

Statistical analysis

Relationships between PIK3CA mutation status and clinical, histological, and biological parameters were estimated with the chi-squared test. Differences between the mutated and non-mutated populations were judged significant at confidence levels of greater than 95% ($P < 0.05$). Metastasis-free survival (MFS) was determined as the interval between diagnosis and detection of the first metastasis. Survival distributions were estimated with the Kaplan-Meier method [23], and the significance of differences between survival rates was ascertained with the log-rank test [24]. The Cox proportional hazards regression model [25] was used to assess prognostic significance.

Results and Discussion

PIK3CA mutations were identified in 151 (33.4%) of 452 primary breast tumors, in keeping with the results of the largest previous studies, showing mutation rates of 25% to 40% [7,8,11,14,16,18,26-30]. Sixty-four tumors bore PIK3CA mutations located in exon 9, 86 tumors bore mutations in exon 20, and one tumor bore mutations in both exons 9 and 20 (Table 1). Exon 20 was thus the most frequently mutated PIK3CA

Table 1 PIK3CA mutation profiles

Exon	Nucleotide	Codon	Number of mutations
9	c.1634A > C	Glu545Ala	2
9	c.1636C > A	Gln546Lys	2
9	c.1624 G > A	Glu542Lys	20
9	c.1634A > G	Glu545Gly	1
9	c.1633 G > A	Glu545Lys	32
9	c.1633 G > C	Glu545Gln	1
9	c.1490A > G	Asn497Ser	1
9	c.1636C > A	Gln546Lys	2
9	c.1637A > C	Gln546Pro	1
9	c.1637A > G	Gln546Arg	2
20	c.3203dupA	Asn1068Lys	2
20	c.3140A > T	His1047Leu	8
20	c.3140A > G	His1047Arg	70
20	c.3132T > A	Asn1044Lys	1
20	c.3145 G > C	Gly1049Arg	2
20	c.3155C > A	Thr1052Lys	1
20	c.[3085 > C(+)/3140A > T]	p.[Asp1029His(+)/His1047Leu]	1
20	c.[3140A > T(+)/3197C > T]	p.[His1047Leu(+)/Ala1066Val]	1
9+20	c.[1624 G < A(+)/3127A > G]	p.[Glu542Lys(+)/Met1043Val]	1

Total = 151

exon, in keeping with most other studies [7,8,11,14,26,28-30]. Among the 151 tumors with *PIK3CA* mutations, three bore double mutations: two in exon 20 (D1029H and H1047R, H1047R and A1066V) and one in exons 9 and 20 (E542K and M1043V). Rare double *PIK3CA* mutations have been reported elsewhere [7,8,30]. We also observed two c.3203dupA frameshift mutations that would change the last C-terminal amino acid (N1068K) of the *PIK3CA* protein and add another three amino acids. N1068K represents 50% of all *PIK3CA* mutations in hepatocellular carcinoma [28] but its possible role in tumor initiation or progression is unknown.

Table 2 shows links between *PIK3CA* mutation status and standard clinical, pathological, and biological characteristics of breast cancer. *PIK3CA* mutations were significantly associated (chi-squared test) with low histopathological grade, small macroscopic tumor size,

and ER α ⁺, PR⁺, and ERBB2⁻ tumors. For example, *PIK3CA* mutations were observed in 52.7% (29 out of 55) of histopathological grade I tumors, 36.8% (84 out of 228) of grade II tumors, and 23.3% (37 out of 159) of grade III tumors. These relationships have also been found in most previous studies [3,7,10,11]. For example, Kalinsky and colleagues [11], like us, found that *PIK3CA* mutations were associated with low histopathological grade and ER α ⁺, PR⁺, and ERBB2⁻ tumors. However, it is noteworthy that, in several studies, no significant association between *PIK3CA* mutations and important clinical or pathological features was found [30]. A high frequency of *PIK3CA* mutations has also been found in lobular carcinoma [16,31]. In agreement with other authors [27,30], we observed a similar frequency of *PIK3CA* mutations in lobular carcinomas (34.5%, 10 out of 29) and ductal carcinomas (33.2%, 129 out of 388) of the breast (Table 2).

Table 2 Relationship between *PIK3CA* mutation status and standard clinical, pathological, and biological features of breast cancer

	Total population number (percentage)	Number of patients (percentage)		P value ^a
		<i>PIK3CA</i> wild-type	<i>PIK3CA</i> -mutated	
Total	452 (100.0)	301 (66.6)	151 (33.4)	
Age, years				
≤ 50	96 (21.2)	66 (21.9)	30 (19.9)	NS
> 50	356 (78.8)	235 (78.1)	121 (81.1)	
SBR histological grade ^{b, c}				
I	55 (12.4)	26 (8.9)	29 (19.3)	0.00021
II	228 (51.6)	144 (49.3)	84 (56.0)	
III	159 (36.0)	122 (41.8)	37 (24.7)	
Lymph node status ^d				
0	115 (25.5)	78 (26.0)	37 (24.5)	
1-3	237 (52.5)	157 (52.3)	80 (53.0)	
> 3	99 (22.0)	65 (21.7)	34 (22.5)	NS
Macroscopic tumor size ^e				
≤ 25 mm	217 (48.8)	135 (45.2)	82 (56.2)	0.029
> 25 mm	228 (51.2)	164 (54.8)	64 (43.8)	
ER α status				
Negative	117 (25.9)	97 (32.2)	20 (13.2)	0.000014
Positive	335 (74.1)	204 (67.8)	131 (86.8)	
PR status				
Negative	194 (42.9)	150 (49.8)	44 (29.1)	0.000028
Positive	258 (57.1)	151 (50.2)	107 (70.9)	
ERBB2 status				
Negative	351 (77.7)	225 (74.8)	126 (83.4)	0.036
Positive	101 (22.3)	76 (25.2)	25 (16.6)	
Histology				
Ductal	388 (85.8)	259 (86.0)	129 (85.5)	NS
Lobular	29 (6.4)	19 (6.3)	10 (6.6)	
Others	35 (7.8)	23 (7.7)	12 (7.9)	

^aChi-squared test. ^bScarff-Bloom-Richardson (SBR) classification. ^cInformation available for 442 patients. ^dInformation available for 451 patients. ^eInformation available for 445 patients. ER α , estrogen receptor-alpha; NS, not significant; *PIK3CA*, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene; PR, progesterone receptor.

Functional genomic studies have recently shown that breast cancer is a highly heterogeneous disease. Several tumor subtypes, such as basal-like, *ERBB2*⁺, and HR⁺ (luminal A and luminal B), can be distinguished on the basis of their gene expression profiles, pointing to the involvement of different oncogenetic pathways. In keeping with this possibility, we observed a marked difference in the *PIK3CA* mutation frequency across four major tumor subgroups: HR⁺/*ERBB2*⁺ (28.3%, 15 out of 53), HR⁺/*ERBB2*⁻ (41.1%, 118 out of 287), HR⁻/*ERBB2*⁺ (20.8%, 10 out of 48), and HR⁻/*ERBB2*⁻ (12.5%, 8 out of 64) ($P = 0.00009$). Being found in 41.1% of cases, *PIK3CA* mutations might thus be characteristic of the luminal subtype (HR⁺/*ERBB2*⁻). We also observed a low frequency (12.5%) of *PIK3CA* mutations in triple-negative tumors (ER⁻/PR⁻/*ERBB2*⁻), a subgroup reported to overlap with the basal-like subtype of breast cancer. Stemke-Hale and colleagues [8] also observed a marked difference in *PIK3CA* mutation frequency across breast tumor subtypes, and *PIK3CA* mutations were more common in HR⁺ tumors (39%) and *ERBB2*⁺ tumors (25%) than in basal-like tumors (13%).

In the overall population of 452 patients, *PIK3CA* mutation was associated with more favorable MFS ($P = 0.0056$) (Table 3 and Figure 1a). The outcome of the 151 patients with *PIK3CA* mutations was thus significantly better than that of the 301 wild-type patients, as was demonstrated by 5-year and 15-year survival rates in these two groups (5-year MFS of 81.0% versus 69.6% and 15-year MFS of 65.8% versus 53.4%). Differences in treatment are unlikely to account for this difference, as *PIK3CA* mutations were as frequent in patients who received postoperative adjuvant chemotherapy or hormone therapy or both (126 out of 366, 34.4%) as in those who received neither treatment (25 out of 86, 29.1%).

These data confirm the results of smaller series of breast tumors, in which *PIK3CA* mutations were significantly associated with more favorable MFS [13,14]. However, unlike Barbareschi and colleagues [16], who found that mutations in the helical (exon 9) and kinase (exon 20) domains of the *PIK3CA* gene had different prognostic values, we found that MFS was similar in patients with mutations in one exon or the other when we compared these two subgroups together and with the wild-type subgroup (Figure 1b).

More interestingly, *PIK3CA* mutation was associated with markedly better MFS in the patients with PR⁺ tumors ($P = 0.0064$) than in those with PR⁻ tumors ($P = 0.71$) (Table 3 and Figure 2a) and also in patients with *ERBB2*⁺ tumors ($P = 0.014$) than in those with *ERBB2*⁻ tumors ($P = 0.12$) (Table 3 and Figure 2b). In contrast, *PIK3CA* mutation was associated only with a trend toward better MFS in patients with ER α ⁺ ($P = 0.082$)

Table 3 *PIK3CA* mutation status according to hormone receptor and *ERBB2* status and relation to metastasis-free survival

	Number of patients	5-year MFS	HR (95% CI)	<i>P</i> value ^a
Total population	452			
Wild-type	301	69.6%	1	0.0056
Mutated	151	81.0%	0.62 (0.44-0.87)	
ER α ⁺	335			
Wild-type	204	75.6%	1	NS
Mutated	131	81.9%	0.71 (0.49-1.04)	
ER α ⁻	117			
Wild-type	97	56.9%	1	NS
Mutated	20	75.0%	0.46 (0.18-1.15)	
PR ⁺	258			
Wild-type	151	77.8%	1	0.0064
Mutated	107	86.6%	0.52 (0.33-0.83)	
PR ⁻	194			
Wild-type	150	61.3%	1	NS
Mutated	44	67.6%	0.91 (0.55-1.50)	
<i>ERBB2</i> ⁺	101			
Wild-type	76	59.9%	1	0.014
Mutated	25	88.0%	0.31 (0.12-0.79)	
<i>ERBB2</i> ⁻	351			
Wild-type	225	72.9%	1	NS
Mutated	126	79.7%	0.75 (0.51-1.08)	

^aUnivariate Cox analysis. CI, confidence interval; ER α , estrogen receptor-alpha; HR, hazard ratio; MFS, metastasis-free survival; NS, not significant; PR, progesterone receptor.

and ER α ⁻ ($P = 0.098$) tumors (Table 3). Accordingly, Loi and colleagues [18] did not find statistically significant difference in survival between *PIK3CA* wild-type and *PIK3CA*-mutated tumors in the ER⁺ population. However, it is noteworthy that these authors described a *PIK3CA* mutation-associated gene expression signature predicting favorable survival in ER⁺ breast cancer [18].

Using a Cox proportional hazards model, we also assessed the MFS predictive value of the parameters that were significant in univariate analysis (that is, Scarff-Bloom-Richardson histological grade, lymph node status, macroscopic tumor size, and ER α , PR, and *ERBB2* status (Table S1 of Additional file 1) and *PIK3CA* mutation status). The prognostic significance of *PIK3CA* mutation status persisted in the *ERBB2*⁺ tumor subgroup ($P = 0.023$) (Table 4) but not in the total tumor population or in the PR⁺ tumor subgroup. Since the patients were not treated with *ERBB2*-targeted




Figure 1 Whole population survival curves. (a) Metastasis-free survival curves of patients with *PIK3CA* wild-type and -mutated tumors. (b) Metastasis-free survival curves of patients with exon 9 *PIK3CA*-mutated tumors, exon 20 *PIK3CA*-mutated tumors, and *PIK3CA* wild-type tumors. Comparison of these curves did not show any statistically significant difference. *PIK3CA*, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene.




Figure 2 Subgroup analysis survival curves. (a) Metastasis-free survival curves of progesterone receptor-positive (PR^+) patients with *PIK3CA* wild-type and -mutated tumors. (b) Metastasis-free survival curves of $ERBB2^+$ patients with *PIK3CA* wild-type and -mutated tumors. *PIK3CA*, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene.

Table 4 Multivariate Cox analysis of metastasis-free survival in the total population and in subgroups of patients with breast cancer

Variables	Total population		ER ⁺ patients		ER ⁻ patients		PR ⁺ patients		PR ⁻ patients		ERBB2 ⁺ patients		ERBB2 ⁻ patients	
	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a	HR (95% CI)	P value ^a
SBR		0.038		0.019		NS		0.00077		NS		NS		0.0043
I	1		1		1		1		1		1		1	
II	1.34 (1.02-1.76)		1.45 (1.06-1.98)		1.02 (0.57-1.80)		1.88 (1.30-2.71)		0.93 (0.63-1.38)		0.89 (0.51-1.55)		1.60 (1.16-2.21)	
III	1.79 (1.03-3.11)		2.11 (1.13-3.92)		1.03 (0.33-3.26)		3.52 (1.69-7.32)		0.87 (0.40-1.91)		0.79 (0.26-2.39)		2.56 (1.34-4.90)	
pN		0.00014		0.00093		NS		0.0068		0.01		0.000049		NS
0	1		1		1		1		1		1		1	
1-3	1.58 (1.25-1.99)		1.60 (1.21-2.11)		1.45 (0.94-2.25)		1.61 (1.14-2.27)		1.51 (1.10-2.07)		2.61 (1.63-4.18)		1.26 (0.97-1.66)	
> 3	2.48 (1.56-3.96)		2.56 (1.47-4.47)		2.11 (0.88-5.05)		2.59 (1.30-5.18)		2.28 (1.21-4.29)		6.83 (2.67-17.44)		1.60 (0.93-2.74)	
pT		0.01		0.00041		NS		0.0023		NS		NS		0.0054
≤ 25 mm	1		1		1		1		1		1		1	
> 25 mm	1.53 (1.11-2.13)		2.05 (1.38-3.05)		0.80 (0.44-1.47)		2.09 (1.30-3.36)		1.17 (0.74-1.84)		1.06 (0.54-2.08)		1.72 (1.17-2.52)	
ER		NS		-		-		NS		NS		NS		NS
Negative	1		-		-		1		1		1		1	
Positive	1.04 (0.68-1.60)		-		-		2.09 (0.28-15.63)		0.82 (0.51-1.32)		0.78 (0.36-1.70)		1.23 (0.71-2.11)	
PR		NS		NS		NS		-		-		NS		NS
Negative	1		1		1		-		-		1		1	
Positive	0.77 (0.52-1.14)		0.81 (0.54-1.23)		0.31 (0.04-2.33)		-		-		0.56 (0.23-1.36)		0.79 (0.51-1.23)	
ERBB2		NS		NS		NS		NS		NS		-		-
Negative	1		1		1		1		1		-		-	
Positive	1.12 (0.77-1.62)		1.01 (0.60-1.70)		1.33 (0.74-2.38)		0.98 (0.50-1.93)		1.17 (0.74-1.85)		-		-	
PIK3CA		NS		NS		NS		NS		NS		0.023		NS
Wild-type	1		1		1		1		1		1		1	
Mutated	0.75 (0.53-1.07)		0.84 (0.57-1.23)		0.49 (0.19-1.26)		0.62 (0.38-1.01)		0.92 (0.55-1.54)		0.31 (0.12-0.79)		0.96 (0.65-1.44)	

^aMultivariate Cox analysis. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; NS, not significant; *PIK3CA*, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene; pN, number of positive axillary lymph nodes assessed by a pathologist at the time of surgery; PR, progesterone receptor; pT, size of the primary tumor assessed by a pathologist at the time of surgery; SBR, Scarff-Bloom-Richardson classification.

treatment, these results address the outcome of ERBB2⁺ tumors affected by surgery and chemotherapy but not targeted therapy like trastuzumab or lapatinib. The independent prognostic value of *PIK3CA* mutation status in patients with ERBB2⁺ breast cancer should now be

tested in a larger series of patients included in randomized prospective ERBB2-based clinical trials.

PIK3CA mutation is also an emerging tumor marker that, in the future, might be used in the process of choosing a treatment. Indeed, ERBB2 inhibitors

(trastuzumab and lapatinib) are clinically active in women with ERBB2⁺ breast cancer, but recent studies suggest that *PIK3CA*-mutated tumors could be resistant to these drugs [32,33]. There is also evidence showing that tumors with PI3K/AKT pathway activation including PTEN loss or *PIK3CA* mutation or both are less sensitive to trastuzumab treatment [17]. Interestingly, this resistance appears to be reversed by mammalian target of rapamycin (mTOR) or PI3K inhibitors [33]. A final validation of *PIK3CA* mutation as an independent predictor of the response to trastuzumab treatment in ERBB2⁺ breast cancer needs a prospective randomized study. Our results also support the emerging role of *PIK3CA* mutation status in the management of future gene-based therapies (ERBB2, mTOR, or PI3K inhibitors used alone or in combination) for breast cancer, particularly in patients with tumors with activated PI3K/AKT pathway [34,35]. *ERBB2* amplification and *PIK3CA* mutation were recently validated as biomarkers of sensitivity to single-agent PI3K inhibitor (GDC-0941) therapy in breast cancer models [35].

Conclusions

This study of 452 breast tumors confirms the high prevalence (33.4%) of *PIK3CA* mutations. The frequency of *PIK3CA* mutations differed markedly according to *ERα*, *PR*, and *ERBB2* status, from 12.5% in triple-negative tumors to 41.1% in the HR⁺/ERBB2⁻ subgroup. Subgroup analysis of patient survival identified *PIK3CA* mutation status as an independent prognostic value in patients with ERBB2⁺ breast cancer. These findings should be confirmed in larger series of patients included in a randomized prospective ERBB2-based clinical trial. Then *PIK3CA* mutation status could serve as a new independent prognostic tool when selecting targeted therapies for patients with ERBB2⁺ breast cancer.

Additional material

Additional file 1: Table S1. Characteristics of the 452 primary breast tumors, and relation to metastasis-free survival. A table showing metastasis free survival of the patients in relation to pathological data.

Abbreviations

ALB: albumin; ERα: estrogen receptor-α; HR: hormone receptor; MFS: metastasis-free survival; mTOR: mammalian target of rapamycin; PCR: polymerase chain reaction; PI3K: phosphatidylinositol 3-kinase; *PIK3CA*: phosphatidylinositol 3-kinase: catalytic: alpha polypeptide gene; PR: progesterone receptor; RT-PCR: reverse transcriptase-polymerase chain reaction; TKR: tyrosine kinase receptor.

Acknowledgements

This work was supported by the Conseil régional d'Ile-de-France, the Cancéropôle Ile-de-France, the Comité départemental des Hauts-de-Seine de la Ligue Nationale Contre le Cancer, and the Association pour la Recherche en Cancérologie de Saint-Cloud (ARCS).

Author details

¹Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France. ²Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Puskinova 6, Olomouc, 77520, Czech Republic. ³Département d'Epidémiologie Clinique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France.

Authors' contributions

AS and SV helped to conceive the approach to mutational analysis, design the primers, and carry out the mutational analysis. CA helped to conceive the approach to mutational analysis, design the primers, and perform the DNA extraction. MC helped to carry out the mutational analysis and draft the manuscript. GC-C and EF performed the statistical analysis. IB and RL helped to draft the manuscript and conceive the study and participated in its design and coordination. KD helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 31 January 2011 Revised: 5 January 2012

Accepted: 13 February 2012 Published: 13 February 2012

References

1. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. *Oncogene* 2008, **27**:5486-5496.
2. Dillon RL, White DE, Muller WJ: The phosphatidylinositol 3-kinase signaling network: implications for human breast cancer. *Oncogene* 2007, **26**:1338-1345.
3. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, DeLong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PI3K promotes cell growth and invasion of human cancer cells. *Cancer Cell* 2005, **7**:561-573.
4. Karakas B, Bachman KE, Park BH: Mutation of the PIK3CA oncogene in human cancers. *Br J Cancer* 2006, **94**:455-459.
5. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc Natl Acad Sci USA* 2005, **102**:18443-18448.
6. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. *Proc Natl Acad Sci USA* 2006, **103**:1475-1479.
7. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005, **65**:2554-2559.
8. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008, **68**:6084-6091.
9. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconail L, Gelman R, Polyak K: PIK3CA mutations in situ and invasive breast carcinomas. *Cancer Res* 2010, **70**:5674-5678.
10. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res* 2009, **69**:4116-4124.
11. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnyak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME: PIK3CA mutation associates with improved outcome in breast cancer. *Clin Cancer Res* 2009, **15**:5049-5059.
12. Li SY, Rong M, Grieco F, Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. *Breast Cancer Res Treat* 2006, **96**:91-95.

13. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S: **Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.** *Clin Cancer Res* 2007, **13**:408-414.
14. Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O: **PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.** *Clin Cancer Res* 2007, **13**:3577-3584.
15. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ: **Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.** *Breast Cancer Res* 2011, **13**:R21.
16. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammasro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A: **Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.** *Clin Cancer Res* 2007, **13**:6064-6069.
17. Esteve FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D: **PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.** *Am J Pathol* 2010, **177**:1647-1656.
18. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C: **PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.** *Proc Natl Acad Sci USA* 2010, **107**:10208-10213.
19. Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M: **Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.** *Clin Chem* 1999, **45**:1148-1156.
20. Bièche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R: **Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.** *Oncogene* 2001, **20**:8109-8115.
21. Onody P, Bertrand F, Muzeau F, Bièche I, Lidereau R: **Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer.** *Arch Pathol Lab Med* 2001, **125**:746-750.
22. Bossard C, Bieche I, Le Doussal V, Lidereau R, Sabourin JC: **Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.** *Anticancer Res* 2005, **25**:4679-4683.
23. Kaplan EL, Meier P: **Nonparametric estimation from incomplete observations.** *J Am Stat Assoc* 1958, **53**:457-481.
24. Peto R, Pike MC, Armitage P: **Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.** *Br J Cancer* 1977, **35**:1-39.
25. Cox DR: **Regression models and life-tables.** *J R Stat Soc Series B Stat Methodol* 1972, **34**:187-220.
26. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: **The PIK3CA gene is mutated with high frequency in human breast cancers.** *Cancer Biol Ther* 2004, **3**:772-775.
27. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA: **Mutation of the PIK3CA gene in ovarian and breast cancer.** *Cancer Res* 2004, **64**:7678-7681.
28. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH: **PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.** *Oncogene* 2005, **24**:1477-1480.
29. Gonzalez-Angulo AM, Stenke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Bertram F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT: **Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.** *Clin Cancer Res* 2009, **15**:2472-2478.
30. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A: **PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.** *Diagn Mol Pathol* 2009, **18**:200-205.
31. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A: **PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.** *J Pathol* 2006, **208**:350-355.
32. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stenke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R: **A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.** *Cancer Cell* 2007, **12**:395-402.
33. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J: **Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BE235.** *Cancer Res* 2008, **68**:9221-9230.
34. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM: **Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BE235 in HER2 amplified and PIK3CA mutant breast cancer cells.** *Proc Natl Acad Sci USA* 2009, **106**:22299-22304.
35. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR: **Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.** *Clin Cancer Res* 2010, **16**:3670-3683.

doi:10.1186/bcr3113

Cite this article as: Cizkova et al.: *PIK3CA* mutation impact on survival in breast cancer patients and in ER α , PR and ERBB2-based subgroups. *Breast Cancer Research* 2012 **14**:R28.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

